ABSTRACT
Background The effectiveness of the domiciliary use of high-flow nasal cannula oxygen therapy (HFNC) in patients with chronic hypercapnic respiratory failure due to chronic obstructive pulmonary disease (COPD) remains controversial.
Objectives To investigate the efficacy and safety of domiciliary HFNC use in stable hypercapnic COPD patients.
Methods This multicenter, open-label, randomized controlled trial enrolled patients with stable hypercapnic COPD. Over 52 weeks, we compared long-term oxygen therapy (LTOT) alone versus domiciliary HFNC plus LTOT (HFNC/LTOT). The primary endpoint was the frequency of moderate/severe COPD exacerbations. We also compared changes from baseline levels in arterial blood gas, SpO2, pulmonary function, health-related quality of life (HRQOL), and a six-minute walk test.
Results We enrolled 104 patients in total; from these, we removed mismatching patients and then assigned 49 and 50 patients to HFNC/LTOT and LTOT groups, respectively, for safety analysis; 47 and 46 patients for HFNC/LTOT and LTOT groups, respectively, for efficacy analysis. Thirty-seven (79%) and 41 patients (89%) in HFNC/LTOT and LTOT, respectively, completed the final evaluation. HFNC significantly reduced the frequency of COPD exacerbations and prolonged the duration without moderate or severe COPD exacerbations over the 52-week study period (p = 0.002, p = 0.032, respectively). The adjusted odds ratios (95% confidence intervals [CIs]) of the frequency of COPD exacerbations in LTOT against HFNC/LTOT was 2.85 (1.48, 5.47). The median survival time (95% CI) to the first COPD exacerbation with moderate or severe for the LTOT group was 25 weeks (14.1, 47.4); however, the HFNC/LTOT group did not reach the median survival time. HFNC also caused statistically significant differences (p < 0.05) in the SpO2, FVC (%FVC), and FEV1 (%FEV1); however, these improvements were transient. There were no other improvements in arterial blood gas, pulmonary function, HRQOL, or six-minute walk test parameters. In addition, no safety concerns were identified for HFNC.
Conclusions HFNC may be a reasonable therapeutic choice in stable hypercapnic COPD patients with a history of exacerbations.
Trial registration number: UMIN000028581, NCT03282019 (http://www.umin/ac.jp, https://clinicaltrials.gov/)
Competing Interest Statement
All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.docx and declare. Horie T reports lecture fee from AstraZeneca, Boehringer Ingelheim, Environmental Restoration and Conservation Agency, Kyorin, Novartis Pharma, and Teijin healthcare. Fukui M reports lecture fee from Teijin Pharma. Sato S reports funding from Nippon Boehringer Ingelheim. Tsuda T reports honoraria from Astrazenea, Nippon Boeringer Ingelheim, and Kyorin. Inoue H reports research/educational grants from Boehringer Ingelheim, GlaxoSmithKline, Kyorin, Novartis, and Teijin-Pharma and lectures/advisory fee from Astellas, AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Kyorin, and Novartis. Tomii K reports lecture fee from Teijin Pharma, Fisher & Paykel, Boehringer Ingelheim, AstraZeneca, and GlaxoSmithKline. No other authors have conflicts of interest to report.
Clinical Trial
UMIN000028581, NCT03282019
Funding Statement
The study was sponsored by the Foundation for Biomedical Research and Innovation at Kobe, with funding from Teijin Pharma Limited under the study contract. The funding source of this study participated in writing the study protocol but had no role in data collection, data management, data analysis, or data interpretation. Kikuchi T, a medical statistician, and Nakagawa Y, a programmer, both of whom analyzed study data, are employees of the Foundation for Biomedical Research and Innovation at Kobe. However, the funding source did not review the analyses nor the current manuscript, and all the work was independent from the funder. English language editing service was provided by Editage (www.editage.jp).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Kobe University Clinical Research Ethical Committee (C180079)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data are available upon reasonable request.
